Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

ZBIO

Phase 2

Obexelimab (CD19xFcyRIIb)

Systemic Lupus Erythematosus (SLE)

H1 2026

SunStone trial. 11/12/24- Trial initiated. Topline results in H1 2026.

Data readout

KPTI

Phase 3

XPOVIO (Selinexor) (XPO1 inhibitor)

TP53 Wild-Type Endometrial Cancer

Mid-2026

XPORT-EC-042 & SIENDO trials. 8/2/23- Initiated pivotal study following the primary analysis of SIENDO study. 11/6/23 New Preliminary Data at IGCS 2023. 6/1/24- Exploratory subgroup analyses at ASCO '24. Top-line data in Mid-2026.

Data readout

ORIC

Phase 1b

ORIC-114 (EGFR/HER2 Inhibitor)

Advanced solid tumors (EGFR, HER2 exon 20 alterations, or HER2 amplification)

Mid-2026

8/10/23- Present initial data at ESMO. 10/21/23- Initial Ph1 dose escalation data. 4/16/24 First patient dosed in all 3 expansion cohorts w/ NSCLC. 10/23/24 Poster presentation at EORTC-NCI-AACR 2024. 1/13/25- To initiate subq amivantamab cohort in Q1 '25, data in mid-2026.

Data readout

CNTX

Phase 1

CTIM-76

Gynecologic and testicular cancers (CLDN6-positive)

H1 2026

5/2/24- IND cleared. 1/14/25- First patient dosed. 3/20/25- Initial data in H1 2026.

Data readout

MLTX

Phase 3

Sonelokimab

Psoriatic Arthritis (PsA)

H1 2026

ARGO, IZAR-1, IZAR-2 trials. 3/10/24- Reported positive 24-wk data. 8/7/24- Enroll subjects in Q4 2024. 11/13/24- starts Ph3 IZAR program w/ topline week-16 data in H1 2026

Data readout

VRDN

Phase 3

VRDN-003

Thyroid Eye Disease (TED)

H1 2026

REVEAL-1 and REVEAL-2 trials. 12/18/23- Reported positive data in healthy volunteers. Completed positive Type C meeting with FDA. 8/8/24 On track to Initiate two Ph3 clinical trials in August 2024. Topline data in H1 2026 & BLA submission by YE 2026.

Data readout

MNMD

Phase 3

MM120 (lysergide D-tartrate)

Generalized Anxiety Disorder (GAD)

H1 2026

Voyage and Panorama studies. 8/13/24- Initiate two Ph3 program [each w/ Part A & Part B] - Voyage Study (MM120-300) in H2 '24 w/ Part A topline data in H1 2026 & Panorama Study (MM120-301) in H1 2025 w/ Part A topline data in H2 2026. 12/16/24- First patient dosed in Voyage study. 1/30/25- First patient dosed in Panorama study.

Data readout

QTTB

Phase 2a

Bempikibart (ADX-914)

Alopecia areata (AA)

H1 2026

SIGNAL-AA trial. 5/9/24- Enrollment completed. 12/10/24- Topline data reported. Expand Ph2a trial and enroll additional patients. 3/8/25- Presented Part A results at AAD'25. Part B on track for initiation in H1 2025 w/ topline data in H1 2026.

Data readout

DTIL

Phase 1/2

ECUR-506

Ornithine Transcarbamylase (OTC) deficiency

H1 2026

OTC-HOPE trial. Collab w/ iECURE. 3/6/24- MHRA approved CTA. 5/7/24 Fast Track Designation. 1/9/25- Reported efficacy & safety data. Finish enrollment in 2025 and provide complete data in H1 2026.

Data readout

PCVX

Phase 2

VAX-31

Infant invasive pneumococcal disease (IPD)

Mid-2026

(Infant IPD) 11/12/24- IND cleared. 12/3/24- Ph2 initiated. 2/5/25- Advanced to second stage. 2/25/25- Topline data in mid-2026, with booster dose results to follow.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20